Munich Cluster for Systems Neurology
print


Breadcrumb Navigation


Content

The USP8 mutational status may predict long-term remission in patients with Cushing's disease.

Clin Endocrinol (Oxf). 2018 Jun 29. doi: 10.1111/cen.13802. [Epub ahead of print]

Authors/Editors: Albani A, Pérez-Rivas LG, Dimopoulou C, Zopp S, Colón-Bolea P, Roeber S, Honegger J, Flitsch J, Rachinger W, Buchfelder M, Stalla GK, Herms J, Reincke M, Theodoropoulou M.
Publication Date: 2018

07_albani

Abstract

OBJECTIVE: Almost half cases of Cushing's disease (CD) tumours carry recurrent activating somatic mutations in the ubiquitin-specific protease 8 gene (USP8) gene. The USP8 mutational status could predict remission in patients with CD, so our objective was to correlate the presence of somatic USP8 mutations with the rate of recurrence after transsphenoidal surgery (TSS) retrospectively.

DESIGN: Biochemical, radiological and clinical data were retrospectively assessed in 48 patients. USP8 mutational status was determined from corticotroph tumour samples. Association between USP8 mutational status, remission and recurrence was investigated.

PATIENTS: Patients with Cushing's disease from a single centre who underwent TSS between 1991 and 2012.

MEASUREMENTS: Long-term remission and recurrence rate after TSS with at least 6 months follow-up. Biochemical, radiological and clinical data, including sex, age at diagnosis, tumour size and preoperative hormonal levels. USP8 mutational status.

RESULTS: Patients with USP8 mutant corticotroph tumours (18 out of 48; 37%) were diagnosed significantly earlier (mean±SD46±10 years vs 53±11 years; P=0.028) and presented with higher preoperative 24 hours urinary-free cortisol levels (median IQR μg/24h 1174.0, 1184.5 vs. 480.0, 405.3; P=0.045). The incidence of recurrence in a 10-year follow-up was significantly higher in patients with USP8 mutant tumours after the initial remission (58% vs. 18% P=0.026). Recurrence appeared significantly earlier in these patients (months 70, 44-97 95%CI vs. 102, 86-119 95%CI; P=0.019).

CONCLUSION: Recurrence appears to be more frequent and earlier after TSS in patients with USP8 mutant corticotroph tumours. This article is protected by copyright. All rights reserved.

 

Related Links